| Literature DB >> 32021313 |
Ajaree Rayanakorn1, Wasan Katip2, Bey Hing Goh3,4, Peninnah Oberdorfer5, Learn Han Lee1.
Abstract
PURPOSE: Streptococcus suis (S. suis) is an emerging zoonotic disease mainly in pigs, causing serious infections in humans with high prevalence in Southeast Asia. Despite a relatively high mortality rate, there are limited data regarding the risk factors of this life-threatening infection. Therefore, a 13-year retrospective cohort study in Chiang Mai, Thailand during 2005-2018 was conducted to explore risk factors associated with S. suis mortality and to update the outcomes of the disease. PATIENTS AND METHODS: S. suis positive cases were derived from those with positive S. suis isolates from microbiological culture results and Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF). Potential risk factors of mortality were identified using univariate and multivariate logistic regression.Entities:
Keywords: S. suis; S. suis infection; Streptococcus suis; Thailand; mortality; risk factor
Year: 2019 PMID: 32021313 PMCID: PMC6941973 DOI: 10.2147/IDR.S233326
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Patients' identification and selection.
Abbreviation: OPD, Outpatient department.
Patient Characteristics
| Characteristics | Total (n=133) |
|---|---|
| Age (years) (mean±SD) | 56.47 ± 13.68 |
| Male | 92 (69.17%) |
| Female | 41 (30.83%) |
| GCS | 12.65 ± 3.15 |
| SAPS II | 27.05 ± 13.89 |
| Relevant social behavior | |
Consumption of raw pork | 49 (36.84%) |
Recent contact with pigs/pork exposure | 5 (3.76%) |
Pig-related occupation | 3 (2.26%) |
Skin injury | 2 (1.50%) |
Alcohol drinking | 66 (49.62%) |
No | 24 (18.05%) |
| Underlying diseases | |
DM | 26 (19.55%) |
ALD | 16 (12.03%) |
Splenectomy | 2 (1.50%) |
VHD | 44 (33.08%) |
Cancer | 2 (1.50%) |
Corticosteroids use | 3 (2.26%) |
HIV/AIDS | 2 (1.50%) |
Spondylodiscites | 27 (20.30%) |
SLE | 21 (15.79%) |
| Exposure to onset (days) (mean±SD)† | 7.67 ± 11.66 |
| Time from exposure to admission (days) (mean±SD)‡ | 13.55 ± 19.21 |
Notes: †Available data from 37 patients; ‡available data from 40 patients.
Abbreviations: GCS, Glasgow coma scale; SAPS II, The Simplified Acute Physiology Score; DM, Diabetes Mellitus; ALD, Alcoholic liver disease; HIV, Human immunodeficiency virus infection; AIDS, Acquired immune deficiency syndrome; SLE, Systemic lupus erythematosus; VHD, Valvular heart disease.
Figure 2Number of S. suis cases admitted at CMUH from 2005–2018.
Figure 3(A and B) Number of S. suis cases admitted at CMUH by month from 2005–2018.
Clinical Manifestations and Outcomes
| Characteristics | Total (n=133) |
|---|---|
| Signs and symptoms | |
Diarrhea | 37 (27.82%) |
Vomiting | 27 (20.03%) |
Vertigo | 10 (7.52%) |
Neck stiffness | 47 (35.34%) |
| Major clinical manifestation | |
Acute meningitis | 50 (37.59%) |
Septicemia | 74 (55.64%) |
Septic shock | 20 (15.04%) |
IE | 34 (25.56%) |
| ● Aortic valve | 26 (19.55%) |
| ● Mitral valve | 19 (14.29%) |
| ● Tricuspid valve | 4 (3.01%) |
| ● Pulmonary valve | 2 (1.50%) |
| ● Aortic, mitral | 3 (2.26%) |
| ● Tricuspid, mitral | 1 (0.75%) |
| ● Aortic, tricuspid, mitral | 1 (0.75%) |
Arthritis | 9 (6.77%) |
Infective spondylodiscitis | 12 (9.02%) |
| Complications | |
Any hearing loss | 42 (31.58%) |
Mild SNHL | 13 (9.77%) |
Moderate SNHL | 7 (5.26%) |
Severe SHNL | 4 (3.01%) |
Profound SNHL | 12 (9.02%) |
Valve replacement | 20 (15.04%) |
Vestibular dysfunction | 30 (22.56%) |
Endophthalmitis | 2 (1.50%) |
| Outcomes | |
Recovered | 70 (52.73%) |
Recovered with sequelae | 44 (33.08%) |
Not recovered | 1 (0.75%) |
Death | 16 (12.03%) |
| Mean duration of admission (days) | 18.18 ± 17.09 |
| Main antibiotic regimen use | |
Ceftriaxone | 47 (36%) |
Ceftriaxone+Others | 49 (37%) |
PGS/Ampicillin | 10 (7%) |
PGS/Ampicillin+Others | 5 (4%) |
Others | 21 (16%) |
| Received dexamethasone | 27 (20.30%) |
Time to microbiological cure (days) ±SD | 8.82 ± 14.04 |
Note: Treatment and outcomes were unavailable in 1 patient.
Abbreviations: IE, Infective endocarditis; SNHL, Sensorineural hearing loss; PGS, Penicillin G, Others include vancomycin in combination with gentamicin and levofloxacin, cefotaxime in combination with vancomycin or metronidazole, ciprofloxacin, clindamycin, and doxycycline.
Figure 4Main antibiotic therapy use.
Laboratory Investigations
| Characteristics | Total |
|---|---|
| Total bilirubin (0.00–1.20 mg/dL) (n=113) | 1.78 ± 3.33 |
| Direct bilirubin (>,=0.30mg/dL) (n=113) | 0.89 ± 2.01 |
| WBCs count (cells/cu.mm) (5000–10,000) (n=129) | 19,897.21 ± 37,555.65 |
| Total protein (6.6–8.7g/dL) (n=113) | 6.65 ± 0.94 |
| Platelet count (cells/cu.mm) (n=130) | 221,983 ± 143,810 |
| Albumin (3.2–5.2 g/dL) (n=113) | 3.12 ± 0.59 |
| Globulin (3.1–3.5 g/dL) (n=113) | 3.53 ± 0.80 |
| BUN (6–20 mg/dL) (n=129) | 25.64 ± 22.71 |
| AST (0–40 U/L) (n=113) | 100.31 ± 161.64 |
| ALT (0–41 U/L) (n=113) | 62.23 ± 66.93 |
| Hb (g/dL) (10–15) (n=130) | 11.58 ± 2.58 |
| Hct (%) (40–50) (n=130) | 35.20 ± 7.876 |
| Microbiological results: | |
| ● Mean MIC to penicillin (µg/mL) ±SD | 0.16 ± 0.16 |
| ● Mean MIC to ceftriaxone (µg/mL) ±SD | 0.24 ± 0.27 |
Abbreviations: WBC, white blood cells; BUN, Blood Urea Nitrogen; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; Hb, Hemoglobin; Hct, Hematocrit; MIC, Minimal Inhibitory Concentration.
Significant Predictors of S. Suis Mortality
| Predictors | Univariate Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value | |
| GCS <8 | 9.42 | 2.08–42.55 | 0.0058 | 1.71 | 0.10–28.50 | 0.709 |
| Time to microbiological cure ≥ 6 days | 6.21 | 1.35–28.55 | 0.0052 | |||
| ALD | 4.38 | 1.29–14.93 | 0.0262 | 2.24 | 0.32–15.84 | 0.417 |
| Acute meningitis | 0.21 | 0.045–0.95 | 0.0176 | 0.24 | 0.03–2.33 | 0.236 |
| Septic shock | 12.39 | 3.86–39.79 | <0.001 | |||
| Direct bilirubin >1.5 mg/dL | 5.30 | 1.77–15.88 | 0.0024 | |||
| Creatinine >1.8 mg/dL | 4.73 | 1.60–13.96 | 0.0050 | 0.41 | 0.01–6.49 | 0.414 |
| Bicarbonate <18 mmol/L | 4.91 | 1.60–15.04 | 0.0073 | 3.00 | 0.12–73.62 | 0.500 |
| Albumin <3.5 g/dL | 5.04 | 1.10–23.21 | 0.0149 | 10.97 | 0.96–125.81 | 0.054 |
Note: All significant predictors, their 95% confidence intervals and p-value are indicated in bold.
Clinical Characteristics of S. Suis Infected Patients for Mortality
| Characteristics | Total | Died (n=16, 12.03%) | Survived (n=117, 87.97%) | OR | 95% CI | p-value | ||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | |||||
| Age (years) (mean±SD) | 56.47± 13.68 | 58.25±15.61 | NA | 56.23±13.46 | NA | 1.01 | 0.97–1.05 | 0.578 |
| Male sex | 92 (69.17%) | 11 | 68.75 | 81 | 69.23 | 0.98 | 0.32–3.02 | 0.969 |
| GCS < 8 | NA | 9.92± 3.95 | NA | 13.06± 2.83 | NA | 9.42 | 2.08–42.55 | 0.006 |
| SAPS II > 50 | NA | 46.56± 17.64 | NA | 24.34±10.87 | NA | 21.97 | 5.40–89.42 | <0.001 |
| Time to microbiological cure ≥ 6 days | NA | 6.33± 3.44 | NA | 8.96± 14.39 | NA | 6.21 | 1.35–28.55 | 0.005 |
| Underlying disease | ||||||||
VHD | 44 (33.08%) | 5 | 11.36 | 39 | 88.64 | 0.91 | 0.30–2.80 | 0.868 |
ALD | 16 (12.03%) | 5 | 31.25 | 11 | 68.75 | 4.38 | 1.29–14.93 | 0.026 |
DM | 26 (19.55%) | 4 | 15.38 | 22 | 84.62 | 1.43 | 0.42–4.89 | 0.568 |
| Major clinical manifestations | ||||||||
Acute meningitis | 50 (37.59%) | 2 | 4 | 48 | 96 | 0.21 | 0.04–0.95 | 0.018 |
Septicemia | 74 (55.64%) | 12 | 16.22 | 62 | 83.78 | 2.66 | 0.81–8.73 | 0.088 |
Septic shock | 20 (15.27%) | 9 | 45.00 | 11 | 55.00 | 12.39 | 3.86–39.79 | <0.001 |
IE | 34 (25.56%) | 3 | 8.82 | 31 | 91.18 | 0.64 | 0.17–2.40 | 0.493 |
| Received dexamethasone | 27 (20.30%) | 1 | 3.740 | 26 | 96.30 | 0.23 | 0.03–1.85 | 0.096 |
| Total bilirubin >2.5 mg/dL | 1.78±3.33 | 4.90±8.19 | NA | 1.30±1.17 | NA | 3.90 | 1.33–11.41 | 0.013 |
| Direct bilirubin >1.5mg/dL | 0.89±2.01 | 2.74±4.89 | NA | 0.60±0.76 | NA | 5.30 | 1.77–15.88 | 0.002 |
| WBC count (cells/cu.mm) | 19,897±37,555 | 15,117± 8512.37 | NA | 20,574±39,981 | NA | 1.0 | 1.00–1.00 | 0.472 |
| AST >300 U/L | 100.31± 161.64 | 179.53±252.09 | NA | 88.18±140.98 | NA | 2.0 | 0.67–6.01 | 0.228 |
| ALT >300 U/L | 62.23± 66.93 | 84.33± 110 | NA | 58.84±57.78 | NA | 1.44 | 0.42–4.89 | 0.568 |
| BUN >28 mg/dL | 25.64± 22.71 | 38.25± 42.83 | NA | 23.86±17.83 | NA | 4.24 | 1.43–12.61 | 0.008 |
| Creatinine > 1.8 mg/dL | 1.80± 2.50 | 3.01± 4.97 | NA | 1.63± 1.90 | NA | 4.73 | 1.60–13.96 | 0.005 |
| Bicarbonate < 18 mmol/L | 21.44± 4.39 | 18.81± 5.86 | NA | 21.82±4.03 | NA | 4.91 | 1.60–15.04 | 0.007 |
| Phosphorus > 4.5 mg/dL | 3.75± 1.90 | 5.27± 3.00 | NA | 3.48± 1.50 | NA | 1.91 | 0.67–5.50 | 0.225 |
| Albumin < 3.5 g/dL | 3.12± 0.59 | 2.75± 0.53 | NA | 3.17± 0.58 | NA | 5.04 | 1.10–23.21 | 0.015 |
| Globulin > 4 g/dL | 3.53± 0.80 | 3.99± 0.87 | NA | 3.46± 0.76 | NA | 2.48 | 0.86–7.14 | 0.092 |